BiotechTube
Home/Pipeline/Next‑Gen CPP Candidates

Next‑Gen CPP Candidates

Obesity

PreclinicalActive

Key Facts

Indication
Obesity
Phase
Preclinical
Status
Active
Company
LIR Life Sciences

About LIR Life Sciences

Innovative transdermal GLP‑1 platform targeting affordable obesity treatment.

View full company profile

Therapeutic Areas

Obesity

Other Obesity Drugs

DrugCompanyPhase
LET003Harbour BioMedDiscovery
LET001Harbour BioMedDiscovery
Anti‑Obesity Oral DrugPremas BiotechPhase 1
Obesity Target Discovery CollaborationFauna BioTarget Discovery/Preclinical
GLP-1 variantsHeligenicsDiscovery
MYO Platform (Metabolic Disease)RenbioPre-clinical
Obesity Clinical TrialsIMA Clinical ResearchNot Applicable (Service)
KAYO-2000KayoTheraPreclinical
MVD-1 (SANA)Eolo PharmaPhase 1
GIP-neutralizing antibodyHelicore BiopharmaPre-clinical
Antral Gastroplasty / Endoscopic SleeveEndo-TAGSSPre-clinical
Undisclosed siRNA ProgramsMoonwalk BiosciencesPre-clinical